GB Sciences, Inc. (GBLX)
| Market Cap | 7.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -394,997 |
| Shares Out | 317.44M |
| EPS (ttm) | 0.01 |
| PE Ratio | 3.31 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 130,854 |
| Open | 0.0252 |
| Previous Close | 0.0272 |
| Day's Range | 0.0226 - 0.0295 |
| 52-Week Range | 0.0200 - 0.0700 |
| Beta | 0.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About GBLX
GB Sciences, Inc. engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
News
TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulatio...
Dr. Andrea Small-Howard explains that Gb Sciences' multicomponent Parkinson's disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that are ...
TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit
President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future successe...
TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference
President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing opioid-base...
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Form...
On March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences' propri...
UPDATE: Gb Sciences Issues Shareholder Letter
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021 Biopharmaceutical research company specializing in...
Gb Sciences Issues Summary Shareholder Letter
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021 Biopharmaceutical research company specializing in...
Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity fo...
Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines 'Cannab...
Gb Sciences Leaves Cannabis Cultivation With $8M Sale Of Las Vegas Facility, Enters BioPharma Industry
Gb Sciences, Inc. (OTCQB:GBLX) announced Tuesday that it has closed the sale of its last remaining cannabis facility, completing a transition to the biopharmaceutical industry. What Happened Based in La...
Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility
The sale will accelerate the development of Gb Sciences' proprietary Parkinson's disease and COVID-related Cytokine-Release Syndrome therapies The sale will accelerate the development of Gb Sciences' pr...
Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety
The biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council of...
Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Supp...
Based on a recently completed preclinical study performed at Michigan State University, Gb Sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixtures ...
Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Invest...
Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Monday...
Gb Sciences to Present at the SNN Network Summer Virtual Event on Wednesday, August 18th, 2021
LAS VEGAS, NV / ACCESSWIRE / August 10, 2021 / Gb Sciences (OTCQB:GBLX), a plant-based research and biopharmaceutical drug development company, today announced that it will be presenting at the SNN Netw...
GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprie...
GB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain from mixtures...
GB Sciences Using AI Technology in Plant-Based Drug Discovery Research
Biotech innovator GB Sciences has launched a drug discovery platform using AI technology that can identify and predict the efficacy of combinations of novel active ingredients from plants. LAS VEGAS, NV...
GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role ...
The UWC also retains John Poss as Chairman and CEO of GB Sciences, Inc. LAS VEGAS, NV / ACCESSWIRE / June 17, 2021 / Dr. Andrea Small-Howard has been promoted to the role of President of GB Sciences, I...
GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
Purisys will supply ultra-high purity cannabinoids for use in GB Sciences' cannabinoid-containing, optimized therapeutic mixtures (OTM). LAS VEGAS, NV / ACCESSWIRE / April 20, 2021 / GB Sciences, Inc. (...
GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform
GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ab...
GB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain Relief
LAS VEGAS, NV / ACCESSWIRE / March 23, 2021 / GB Sciences, Inc. (OTCQB:GBLX) and its Spanish research partners at the Universidad de Sevilla (USE) are pleased to announce the publication of a new scient...
GB Sciences Receives $4,150,000 and Completes the Sale of Its Louisiana Operations to Wellcana Plus
LAS VEGAS, NV / ACCESSWIRE / January 12, 2021 / GB Sciences, Inc. (OTCQB:GBLX) completed the sale of its remaining interest in GB Sciences Louisiana LLC ("GBSLA") on December 16, 2020. In November 2019,...